head of Lilly Oncology. The agreement isn't Lilly's first attempt to make a mark in the PI3K inhibitor class, having previously been working on LOXO-783, a drug it acquired as part of its $8 ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...

Jake Van Naarden, executive vice president and president, Lilly Oncology, will take part in a fireside chat at 1:50 p.m., Eastern time. A live audio webcast will be available on the "Webcasts ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...

Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly to discover, develop and commercialise ...

Eli Lilly’s Bold Bid to Lead Oncology Eli Lilly’s advanced talks to acquire Scorpion Therapeutics for up to $2.5 billion marks a significant leap in the company’s oncology ambitions [1].

In a press release, Lilly chair and CEO David A. Ricks said, “Lilly's optimism about the potential of our pipeline across ...

Advertisement Eli Lilly chairman and Chief Executive Officer ... to produce medicines that support cardio-metabolic health, oncology, immunology and neuroscience treatments.